32.jpg)
56.jpg)
TREATMENT FOR THE DYSFUNCTION OF MEIBOMIAL GLANDS
Patent number:
202230503
No items found.
The present invention relates to a substantially pure population of mesenchymal stem cells to use them in the prophylactic and/or therapeutic treatment for Meibomian gland dysfunction.
Countries:
Spain
Regions:
Community of Madrid
Centers:
UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INST DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
Although there are some current treatments for MGD, there is also an unmet medical need to find alternative treatments that are effective and without side effects. The invention shows that mesenchymal stem cells, mainly those derived from adipose tissue and used allogeneically, are a safe and feasible therapy for the treatment of MGD. Specifically, it shows that patients with MGD-related disease show clear improvements in ocular pain and epithelial defect, visual acuity, and corneal opacity.
Comments
Other related patents
Health
PEPTIDE AND PHARMACEUTICAL COMPOSITIONS OF SAME FOR USE AS AN ANTIMICROBIAL AND IN CANCER TREATMENT
Health
CARBON NANOTUBE COATING FOR USE AS ANCHORING SYSTEM FOR NANOSCALE AND MICROMETRIC SCALE DEVICES WITH THERAPEUTIC ACTIVITY
Health
Other